Revenue
$151.18M
Fiscal year ended 2026-06-30Operating income
-$10.86M
Fiscal year ended 2026-06-30Free cash flow
-$12.14M
Fiscal year ended 2026-06-30HERON THERAPEUTICS, INC. /DE/ (HRTX) reported revenue of $151.18M and net income of -$34.05M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from HERON THERAPEUTICS, INC. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $151.18M |
| Cost of revenue | $45.24M |
| Gross profit | $105.94M |
| Operating income | -$10.86M |
| Net income | -$34.05M |
| Research & development | $12.30M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | Unavailable |
| Income tax expense | Unavailable |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $104.50M |
| General & administrative | $50.85M |
| Selling & marketing | $53.64M |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $20.72M |
| Total assets | $252.26M |
| Current assets | $229.84M |
| Total liabilities | $245.35M |
| Current liabilities | $92.14M |
| Total equity incl. NCI | $6.91M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $90.58M |
| Accounts receivable | $89.57M |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | $11.64M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | -$11.61M |
| Capital expenditures | $529.00K |
| Investing cash flow | $2.20M |
| Financing cash flow | $13.61M |
| Net change in cash | $4.20M |
| Stock-based compensation | $11.18M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $2.13M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | -$12.14M |
| Gross margin | 70.1% |
| Operating margin | -7.2% |
| FCF margin | -8.0% |
| SBC / revenue | 7.4% |
| Current ratio | 2.49x |
| Revenue YoY growth | 1.0% |
| Net margin | -22.5% |
| R&D / revenue | 8.1% |
| CapEx / revenue | 0.3% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HRTX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-06View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.